-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 20, the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration announced that a new class 2.
Screenshot source: CDE official website
According to public information, Nanobiotix is a late-stage clinical development biotechnology company dedicated to bringing new treatment options to patients through physical principles-based treatments
The physical mechanism of action of NBTXR3 is designed to be activated by radiotherapy, induce massive tumor cell death within the injected tumor, and subsequently trigger an adaptive immune response and long-term anticancer memory
In May 2021, LianBio announced a partnership with Nanobiotix to obtain an exclusive license to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore and Thailand
For the HNSCC indication, NBTXR3 has previously produced consistent safety data and early indications of efficacy in a Phase 1 dose escalation and dose expansion study
Head and neck squamous cell carcinoma is a heterogeneous malignancy
References:
[1] The official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China.